Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109359 | 0.83 | KMT2A (0.47) | KMT2AALDH1A1MAPTMEN1SMN1; SMN2 | |
| SCHEMBL161867 | 0.83 | LMNA (0.56) | LMNAKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL8357967 | 0.82 | LMNA (0.53) | LMNAKMT2AALDH1A1MAPTCYP1A2 | |
| SCHEMBL20109336 | 0.81 | MEN1 (0.49) | LMNAKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL20109333 | 0.81 | ALDH1A1 (0.49) | KMT2AALDH1A1MAPTMEN1SMN1; SMN2 | |
| SCHEMBL20109358 | 0.80 | KMT2A (0.48) | LMNAKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL20109356 | 0.80 | MAPT (0.47) | LMNAALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL12694041 | 0.80 | LMNA (0.51) | LMNAKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL398701 | 0.78 | LMNA (0.73) | LMNAKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL3883309 | 0.77 | LMNA (0.54) | LMNAALDH1A1MAPTCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | LMNA 3601/4885KMT2A 2508/4885ALDH1A1 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.